Loading...
•
Dec 31, 2022
Agenus Q4 2022 Earnings Report
Reported financial results and provided a corporate update.
Key Takeaways
Agenus reported revenue of $28 million and a net loss of $74 million for the fourth quarter of 2022. The company ended the year with a cash, cash equivalent, and short-term investment balance of $193 million.
Agenus entered 2023 with strong momentum across its clinical pipeline of immuno-oncology programs.
Botensilimab and balstilimab show exciting potential in combination to treat a broad spectrum of treatment-resistant cancers.
Botensilimab's clinical activity in advanced and refractory cancers has generated considerable interest from experts worldwide.
Agenus is expediting the expansion of its botensilimab/balstilimab development program in MSS CRC and other priority indications.
Forward Guidance
Agenus is focused on advancing its clinical pipeline and strategic partnerships in 2023.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...